Pharmanet Group (ASX: PNO) has been granted patents in the United States for the company’s Tripeptofen project and the Cox2 Inhibitor.
The United States Patent and Trademark Office (USPTO) has awarded the patent applications to Pharmanet’s wholly owned subsidiary Cambridge Scientific.
The first patent granted is one of a number of applications in the region for Tripeptofen, and defines the rights in the use of Pharmanet’s active ingredients in the commercially important anti-inflammatory fields.
The second patent describes the process of producing a form of non-steroidal anti-inflammatory drug that directly targets COX-2, an enzyme responsible for inflammation.
Cambridge Scientific has been granted patents covering the use and manufacture of an Analgesic and/or Anti-inflammatory Composition in Australia, the U.S., India, South Africa and New Zealand.
Pharmanet believes these latest successful patent applications could be replicated in other regions, where the company has corresponding applications in advanced stages of examination.
Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.
Pharmanet Group granted anti-inflammatory patents in the U.S.
Published: 06:20 30 May 2012 BST